新辅助剂camrelizumab加化学治疗局部晚期宫癌 (NACI研究):一个前性,单臂,II期试验的研究方案
Jing Chen1,2, Yingyan Han1,2, Yingjie Hu1,2
1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
这项研究调查了结合新辅助化疗 (NACT) 与camrelizumab,PD-1抑制剂,局部晚期宫癌 (LACC) 的疗效. 这些发现旨在确定新辅助化学免疫疗法作为LACC患者的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 宫癌研究研究 宫癌研究
背景情况:
- 新辅助化疗 (NACT) 是局部晚期子宫癌 (LACC) 的新兴治疗方法,但其与手术和放射治疗一起的最佳使用仍在争论中.
- PD-1 抑制剂在复发性/转移性宫癌中表现有前途,临床前数据表明与NACT的协同作用.
研究的目的:
- 评估camelizumab的疗效和安全性,一个PD-1抑制剂,与NACT结合,作为LACC的手术前治疗.
- 探索新辅助化学免疫疗法的潜力,作为LACC的新治疗策略.
主要方法:
- 这是一项前性的,开放的,单臂的II期研究,涉及82名LACC患者.
- 患者接受了一轮西斯丁和纳布-帕克利塔塞尔NACT治疗,随后接受了两轮卡姆雷利祖马布与NACT联合治疗.
- 治疗反应决定了后续管理:完全/部分响应者接受了手术,而稳定/进展性疾病患者接受了化疗或放射治疗.
主要成果:
- 主要终点是客观响应率.
- 二级终点包括病理完整反应,需要辅助疗法,安全性,手术并发症,无事件生存率和整体生存率.
- 该研究还将评估周围免疫反应和瘤微环境在免疫疗法疗效中的作用.
结论:
- 这项研究是首批评估LACC新辅助化疗免疫疗法的研究之一.
- 预计这些发现将支持新辅助抗PD-1免疫疗法与激进手术相结合,作为LACC的新治疗方法.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
05:56Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
相关概念视频
Treatment Resistant Cancers
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
